BIOCEPT INC (BIOC) Stock Price, Quote, News and Overview
NASDAQ:BIOC - Nasdaq - US09072V6002 - Common Stock - Currency: USD
BIOC Quote, Performance and Key Statistics
0.4349
-0.07 (-13.05%)
The current stock price of BIOC is 0.4349 USD. In the past month the price decreased by -69.16%. In the past year, price decreased by -98.23%.
BIOC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BIOC
Company Profile
Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. The company offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). The company has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.
Company Info
BIOCEPT INC
9955 Mesa Rim Road
San Diego CALIFORNIA 92121 US
CEO: Michael W. Nall
Employees: 50
Company Website: https://biocept.com/
Phone: 18583208200.0
BIOCEPT INC / BIOC FAQ
What is the stock price of BIOCEPT INC today?
The current stock price of BIOC is 0.4349 USD. The price decreased by -13.05% in the last trading session.
What is the ticker symbol for BIOCEPT INC stock?
The exchange symbol of BIOCEPT INC is BIOC and it is listed on the Nasdaq exchange.
On which exchange is BIOC stock listed?
BIOC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOCEPT INC stock?
6 analysts have analysed BIOC and the average price target is 4.08 USD. This implies a price increase of 838.15% is expected in the next year compared to the current price of 0.4349. Check the BIOCEPT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOCEPT INC worth?
BIOCEPT INC (BIOC) has a market capitalization of 1.05M USD. This makes BIOC a Nano Cap stock.
How many employees does BIOCEPT INC have?
BIOCEPT INC (BIOC) currently has 50 employees.
Is BIOCEPT INC (BIOC) expected to grow?
The Revenue of BIOCEPT INC (BIOC) is expected to decline by -93.72% in the next year. Check the estimates tab for more information on the BIOC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOCEPT INC (BIOC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIOC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIOC, evaluating the profitability, health, valuation and growth aspects
- BIOCEPT INC (BIOC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOCEPT INC (BIOC) Sales and EPS estimates to see what analysts future expectations are.
- BIOCEPT INC (BIOC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOCEPT INC (BIOC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOCEPT INC (BIOC) Stock Chart to make your own analysis
- BIOCEPT INC (BIOC) Latest news and press-releases to stay up to date.
Does BIOCEPT INC (BIOC) stock pay dividends?
BIOC does not pay a dividend.
When does BIOCEPT INC (BIOC) report earnings?
BIOCEPT INC (BIOC) will report earnings on 2023-11-20, after the market close.
What is the Price/Earnings (PE) ratio of BIOCEPT INC (BIOC)?
BIOCEPT INC (BIOC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-43.07).
BIOC Technical Analysis
BIOC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BIOC. BIOC may be in some trouble as it scores bad on both profitability and health.
BIOC Financial Highlights
Over the last trailing twelve months BIOC reported a non-GAAP Earnings per Share(EPS) of -43.07. The EPS decreased by -42970% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -239.73% | ||
| ROE | -18271.38% | ||
| Debt/Equity | 4.7 |
BIOC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BIOC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 86.86% and a revenue growth -93.72% for BIOC